AnaptysBio Shares Rise After FDA Expands Jemperli Approval

AnaptysBio shares rose Monday, Oct. 19, after the U.S. Food and Drug Administration (FDA) expanded approval of GSK’s Jemperli for a type of rectal cancer through its accelerated pathway. The decision adds a use to the label for Jemperli, an anti-PD-1 cancer treatment. AnaptysBio is GSK’s partner on the drug. Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.